UA73270C2 - Application of genetically structured cells expressing lymphocytes activation gene (lag-3) on the surface for protection of transplant against rejection and a method for induction of specific protection against rejection of material being tranplanted - Google Patents
Application of genetically structured cells expressing lymphocytes activation gene (lag-3) on the surface for protection of transplant against rejection and a method for induction of specific protection against rejection of material being tranplanted Download PDFInfo
- Publication number
- UA73270C2 UA73270C2 UA99063590A UA99063590A UA73270C2 UA 73270 C2 UA73270 C2 UA 73270C2 UA 99063590 A UA99063590 A UA 99063590A UA 99063590 A UA99063590 A UA 99063590A UA 73270 C2 UA73270 C2 UA 73270C2
- Authority
- UA
- Ukraine
- Prior art keywords
- cells
- gene
- host
- cell
- rejection
- Prior art date
Links
- 210000004027 cell Anatomy 0.000 title claims abstract description 176
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 67
- 238000000034 method Methods 0.000 title claims abstract description 26
- 230000004224 protection Effects 0.000 title claims abstract description 21
- 230000004913 activation Effects 0.000 title claims abstract description 7
- 230000006698 induction Effects 0.000 title claims abstract description 7
- 210000004698 lymphocyte Anatomy 0.000 title claims abstract description 4
- 239000000463 material Substances 0.000 title abstract description 4
- 101100510617 Caenorhabditis elegans sel-8 gene Proteins 0.000 title 1
- 210000000987 immune system Anatomy 0.000 claims abstract description 29
- 102000035160 transmembrane proteins Human genes 0.000 claims abstract description 14
- 108091005703 transmembrane proteins Proteins 0.000 claims abstract description 14
- 210000001519 tissue Anatomy 0.000 claims description 42
- 210000000056 organ Anatomy 0.000 claims description 28
- 101710199257 Peripheral myelin protein 22 Proteins 0.000 claims description 27
- 102000004169 proteins and genes Human genes 0.000 claims description 25
- 238000001415 gene therapy Methods 0.000 claims description 24
- 102100035917 Peripheral myelin protein 22 Human genes 0.000 claims description 23
- 230000014509 gene expression Effects 0.000 claims description 19
- 238000002054 transplantation Methods 0.000 claims description 19
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims description 16
- 108020004414 DNA Proteins 0.000 claims description 15
- 241001465754 Metazoa Species 0.000 claims description 10
- 238000004519 manufacturing process Methods 0.000 claims description 9
- 210000002950 fibroblast Anatomy 0.000 claims description 8
- 239000003446 ligand Substances 0.000 claims description 8
- 210000003098 myoblast Anatomy 0.000 claims description 7
- 230000001939 inductive effect Effects 0.000 claims description 6
- 229940126601 medicinal product Drugs 0.000 claims description 6
- 108091029865 Exogenous DNA Proteins 0.000 claims description 5
- 210000002889 endothelial cell Anatomy 0.000 claims description 5
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims description 5
- 230000001105 regulatory effect Effects 0.000 claims description 5
- 229960002963 ganciclovir Drugs 0.000 claims description 4
- 210000003494 hepatocyte Anatomy 0.000 claims description 4
- 239000003018 immunosuppressive agent Substances 0.000 claims description 4
- 102100034613 Annexin A2 Human genes 0.000 claims description 3
- 108090000668 Annexin A2 Proteins 0.000 claims description 3
- 210000001671 embryonic stem cell Anatomy 0.000 claims description 3
- 230000001605 fetal effect Effects 0.000 claims description 3
- 238000002744 homologous recombination Methods 0.000 claims description 3
- 230000006801 homologous recombination Effects 0.000 claims description 3
- 230000009261 transgenic effect Effects 0.000 claims description 3
- 210000003606 umbilical vein Anatomy 0.000 claims description 3
- 206010010144 Completed suicide Diseases 0.000 claims description 2
- 108020004440 Thymidine kinase Proteins 0.000 claims description 2
- 229940125721 immunosuppressive agent Drugs 0.000 claims description 2
- 238000003780 insertion Methods 0.000 claims description 2
- 230000037431 insertion Effects 0.000 claims description 2
- 230000000392 somatic effect Effects 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims description 2
- 102000006601 Thymidine Kinase Human genes 0.000 claims 1
- 238000012876 topography Methods 0.000 claims 1
- 241000699670 Mus sp. Species 0.000 description 24
- 210000001744 T-lymphocyte Anatomy 0.000 description 17
- 238000011282 treatment Methods 0.000 description 15
- 238000002347 injection Methods 0.000 description 14
- 239000007924 injection Substances 0.000 description 14
- 206010028980 Neoplasm Diseases 0.000 description 12
- 230000000735 allogeneic effect Effects 0.000 description 11
- 150000003839 salts Chemical class 0.000 description 11
- 230000000694 effects Effects 0.000 description 9
- 206010062016 Immunosuppression Diseases 0.000 description 8
- 230000001506 immunosuppresive effect Effects 0.000 description 8
- 210000004988 splenocyte Anatomy 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 150000001413 amino acids Chemical class 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 239000012634 fragment Substances 0.000 description 6
- 230000028993 immune response Effects 0.000 description 6
- 229920001184 polypeptide Polymers 0.000 description 6
- 108090000765 processed proteins & peptides Proteins 0.000 description 6
- 102000004196 processed proteins & peptides Human genes 0.000 description 6
- 239000013598 vector Substances 0.000 description 6
- 101710169336 5'-deoxyadenosine deaminase Proteins 0.000 description 5
- 102000055025 Adenosine deaminases Human genes 0.000 description 5
- 206010052779 Transplant rejections Diseases 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 239000012636 effector Substances 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 230000001472 cytotoxic effect Effects 0.000 description 4
- 230000007812 deficiency Effects 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 239000002243 precursor Substances 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- 230000008719 thickening Effects 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 238000011316 allogeneic transplantation Methods 0.000 description 3
- 210000001185 bone marrow Anatomy 0.000 description 3
- 125000003178 carboxy group Chemical class [H]OC(*)=O 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000003013 cytotoxicity Effects 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- -1 for example Chemical class 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 208000024908 graft versus host disease Diseases 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 210000005260 human cell Anatomy 0.000 description 3
- 230000002480 immunoprotective effect Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 210000004153 islets of langerhan Anatomy 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 210000000663 muscle cell Anatomy 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 210000001082 somatic cell Anatomy 0.000 description 3
- 210000000130 stem cell Anatomy 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 102000053642 Catalytic RNA Human genes 0.000 description 2
- 108090000994 Catalytic RNA Proteins 0.000 description 2
- 231100000023 Cell-mediated cytotoxicity Toxicity 0.000 description 2
- 206010057250 Cell-mediated cytotoxicity Diseases 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 206010011968 Decreased immune responsiveness Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 101100298048 Mus musculus Pmp22 gene Proteins 0.000 description 2
- 208000001388 Opportunistic Infections Diseases 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 108700019146 Transgenes Proteins 0.000 description 2
- 108010067390 Viral Proteins Proteins 0.000 description 2
- 125000003277 amino group Chemical class 0.000 description 2
- 210000004102 animal cell Anatomy 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 210000000612 antigen-presenting cell Anatomy 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 210000002798 bone marrow cell Anatomy 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 230000005890 cell-mediated cytotoxicity Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 238000005538 encapsulation Methods 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000028996 humoral immune response Effects 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 229940124589 immunosuppressive drug Drugs 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 235000019988 mead Nutrition 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 108091092562 ribozyme Proteins 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 239000013603 viral vector Substances 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- YREOLPGEVLLKMB-UHFFFAOYSA-N 3-methylpyridin-1-ium-2-amine bromide hydrate Chemical compound O.[Br-].Cc1ccc[nH+]c1N YREOLPGEVLLKMB-UHFFFAOYSA-N 0.000 description 1
- 101150094765 70 gene Proteins 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 108020004491 Antisense DNA Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010068051 Chimerism Diseases 0.000 description 1
- 102100022641 Coagulation factor IX Human genes 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 102000001039 Dystrophin Human genes 0.000 description 1
- 108010069091 Dystrophin Proteins 0.000 description 1
- 108010076282 Factor IX Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 208000031220 Hemophilia Diseases 0.000 description 1
- 208000009292 Hemophilia A Diseases 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 1
- 108010048209 Human Immunodeficiency Virus Proteins Proteins 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 108700041567 MDR Genes Proteins 0.000 description 1
- 108091054437 MHC class I family Proteins 0.000 description 1
- 101000969137 Mus musculus Metallothionein-1 Proteins 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 208000035467 Pancreatic insufficiency Diseases 0.000 description 1
- 241000282520 Papio Species 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 206010061334 Partial seizures Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 108700005075 Regulator Genes Proteins 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 241001068295 Replication defective viruses Species 0.000 description 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 208000002903 Thalassemia Diseases 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 150000008431 aliphatic amides Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003816 antisense DNA Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 125000003435 aroyl group Chemical group 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 238000010322 bone marrow transplantation Methods 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 210000000234 capsid Anatomy 0.000 description 1
- 125000001589 carboacyl group Chemical group 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000035605 chemotaxis Effects 0.000 description 1
- 230000014107 chromosome localization Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 230000004186 co-expression Effects 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 210000001608 connective tissue cell Anatomy 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 230000001461 cytolytic effect Effects 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000000779 depleting effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229960004222 factor ix Drugs 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 201000007186 focal epilepsy Diseases 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 229930004094 glycosylphosphatidylinositol Natural products 0.000 description 1
- 208000037824 growth disorder Diseases 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 210000005003 heart tissue Anatomy 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229940065638 intron a Drugs 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 230000008949 local secretion Effects 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 210000005033 mesothelial cell Anatomy 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 201000006938 muscular dystrophy Diseases 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 210000000944 nerve tissue Anatomy 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 229920002113 octoxynol Polymers 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 210000002741 palatine tonsil Anatomy 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 210000004738 parenchymal cell Anatomy 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 108010027841 pegademase bovine Proteins 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 229940012957 plasmin Drugs 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 210000005211 primary lymphoid organ Anatomy 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000004952 protein activity Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 201000004193 respiratory failure Diseases 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 208000007056 sickle cell anemia Diseases 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000004114 suspension culture Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 239000002753 trypsin inhibitor Substances 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 238000002689 xenotransplantation Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1841—Transforming growth factor [TGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2066—IL-10
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Toxicology (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Transplantation (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP1996/005280 WO1998023748A1 (en) | 1996-11-29 | 1996-11-29 | Methods for preventing graft rejection in transplantation and for producing a universal gene therapy host cell using lymphocyte activation (lag-3) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA73270C2 true UA73270C2 (en) | 2005-07-15 |
Family
ID=8166413
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UA99063590A UA73270C2 (en) | 1996-11-29 | 1996-11-29 | Application of genetically structured cells expressing lymphocytes activation gene (lag-3) on the surface for protection of transplant against rejection and a method for induction of specific protection against rejection of material being tranplanted |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US6500422B2 (es) |
| EP (1) | EP0941329B1 (es) |
| JP (1) | JP3920928B2 (es) |
| KR (1) | KR100481230B1 (es) |
| AR (1) | AR018489A1 (es) |
| AT (1) | ATE271607T1 (es) |
| AU (1) | AU733825B2 (es) |
| BR (1) | BR9612821A (es) |
| CA (1) | CA2272130C (es) |
| DE (1) | DE69632967T2 (es) |
| DK (1) | DK0941329T3 (es) |
| EA (1) | EA003772B1 (es) |
| ES (1) | ES2225901T3 (es) |
| HK (1) | HK1023599A1 (es) |
| IL (1) | IL130168A (es) |
| NO (1) | NO324378B1 (es) |
| PT (1) | PT941329E (es) |
| UA (1) | UA73270C2 (es) |
| WO (1) | WO1998023748A1 (es) |
| ZA (1) | ZA9710737B (es) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA003772B1 (ru) * | 1996-11-29 | 2003-08-28 | Апплайд Резеч Системз Арс Холдинг Н.В. | Средство для обеспечения защиты трансплантата от отторжения иммунной системой хозяина на основе штамма генетически сконструированных эукариотических клеток, содержащих днк, кодирующую трансмембранный белок lag-3 |
| FI1897548T4 (fi) | 2003-02-28 | 2024-09-03 | The Johns Hopkins University | T-solujen säätely |
| KR20050082389A (ko) * | 2004-02-18 | 2005-08-23 | 메덱스젠 주식회사 | 직렬 연쇄체를 갖는 면역접합체를 포함하는 장기이식합병증 치료용 약제학적 조성물 |
| EP2044949A1 (en) * | 2007-10-05 | 2009-04-08 | Immutep | Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response |
| AR072999A1 (es) * | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| UY34887A (es) | 2012-07-02 | 2013-12-31 | Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware | Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos |
| RS58705B1 (sr) | 2013-09-20 | 2019-06-28 | Bristol Myers Squibb Co | Kombinacija anti-lag-3 antitela i anti-pd-1 antitela za lečenje tumora |
| GB201322626D0 (en) | 2013-12-19 | 2014-02-05 | Immutep S A | Combined preparations for the treatment of cancer |
| JO3663B1 (ar) | 2014-08-19 | 2020-08-27 | Merck Sharp & Dohme | الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين |
| GB201500374D0 (en) | 2015-01-09 | 2015-02-25 | Immutep S A | Combined preparations for the treatment of cancer |
| UA124925C2 (en) | 2015-10-02 | 2021-12-15 | Hoffmann La Roche | Bispecific antibodies specific for pd1 and tim3 |
| BR112018012352A2 (pt) | 2015-12-16 | 2018-12-11 | Merck Sharp & Dohme Corp. | anticorpos anti-lag3 e fragmentos de ligação ao antígeno |
| PE20191494A1 (es) | 2017-04-03 | 2019-10-21 | Hoffmann La Roche | Inmunoconjugados de un anticuerpo anti-pd-1 con un il-2 mutante o con il-15 |
| TWI690538B (zh) | 2017-04-05 | 2020-04-11 | 瑞士商赫孚孟拉羅股份公司 | 特異性結合至pd1至lag3的雙特異性抗體 |
| MX2019012076A (es) | 2017-05-30 | 2019-12-09 | Bristol Myers Squibb Co | Composiciones que comprenden un anticuerpo anti gen-3 de activacion del linfocito (lag-3) o un anticuerpo anti-lag-3 y un anticuerpo anti muerte celular programada 1 (pd-1) o anti ligando 1 de muerte celular programada (pd-l1). |
| MX2019012032A (es) | 2017-05-30 | 2019-10-30 | Bristol Myers Squibb Co | Tratamiento de tumores positivos a gen 3 de activacion de linfocitos (lag-3). |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2656800B1 (fr) * | 1990-01-08 | 1992-05-15 | Roussy Inst Gustave | Nouvelles proteines produits par les lymphocytes humains, sequence d'adn codant pour ces proteines et applications pharmaceutiques et biologiques. |
| US5876708A (en) * | 1992-02-19 | 1999-03-02 | The General Hospital Corporation | Allogeneic and xenogeneic transplantation |
| JP3700859B2 (ja) | 1994-05-06 | 2005-09-28 | アンスティテュ ギュスタブ ルシ | Ｌａｇ−３タンパク質の可溶性ポリペプチドフラクション；製造方法、治療用製剤、抗イディオタイプ抗体 |
| EA003772B1 (ru) * | 1996-11-29 | 2003-08-28 | Апплайд Резеч Системз Арс Холдинг Н.В. | Средство для обеспечения защиты трансплантата от отторжения иммунной системой хозяина на основе штамма генетически сконструированных эукариотических клеток, содержащих днк, кодирующую трансмембранный белок lag-3 |
-
1996
- 1996-11-29 EA EA199900507A patent/EA003772B1/ru not_active IP Right Cessation
- 1996-11-29 IL IL130168A patent/IL130168A/en not_active IP Right Cessation
- 1996-11-29 US US09/319,147 patent/US6500422B2/en not_active Expired - Fee Related
- 1996-11-29 DE DE69632967T patent/DE69632967T2/de not_active Expired - Fee Related
- 1996-11-29 DK DK96940658T patent/DK0941329T3/da active
- 1996-11-29 ES ES96940658T patent/ES2225901T3/es not_active Expired - Lifetime
- 1996-11-29 UA UA99063590A patent/UA73270C2/uk unknown
- 1996-11-29 AT AT96940658T patent/ATE271607T1/de not_active IP Right Cessation
- 1996-11-29 PT PT96940658T patent/PT941329E/pt unknown
- 1996-11-29 JP JP52611398A patent/JP3920928B2/ja not_active Expired - Fee Related
- 1996-11-29 BR BR9612821-6A patent/BR9612821A/pt not_active Application Discontinuation
- 1996-11-29 WO PCT/EP1996/005280 patent/WO1998023748A1/en active IP Right Grant
- 1996-11-29 CA CA002272130A patent/CA2272130C/en not_active Expired - Fee Related
- 1996-11-29 KR KR10-1999-7004274A patent/KR100481230B1/ko not_active IP Right Cessation
- 1996-11-29 AU AU10667/97A patent/AU733825B2/en not_active Ceased
- 1996-11-29 EP EP96940658A patent/EP0941329B1/en not_active Expired - Lifetime
-
1997
- 1997-11-28 AR ARP970105619A patent/AR018489A1/es not_active Application Discontinuation
- 1997-11-28 ZA ZA9710737A patent/ZA9710737B/xx unknown
-
1999
- 1999-05-27 NO NO19992569A patent/NO324378B1/no not_active IP Right Cessation
-
2000
- 2000-05-05 HK HK00102732A patent/HK1023599A1/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| AR018489A1 (es) | 2001-11-28 |
| IL130168A (en) | 2006-09-05 |
| DE69632967D1 (de) | 2004-08-26 |
| DE69632967T2 (de) | 2005-08-11 |
| JP3920928B2 (ja) | 2007-05-30 |
| HK1023599A1 (en) | 2000-09-15 |
| NO992569L (no) | 1999-05-27 |
| PT941329E (pt) | 2004-11-30 |
| NO992569D0 (no) | 1999-05-27 |
| CA2272130C (en) | 2007-10-23 |
| WO1998023748A1 (en) | 1998-06-04 |
| BR9612821A (pt) | 2000-04-11 |
| EA003772B1 (ru) | 2003-08-28 |
| NO324378B1 (no) | 2007-10-01 |
| AU1066797A (en) | 1998-06-22 |
| KR100481230B1 (ko) | 2005-04-07 |
| US20020081282A1 (en) | 2002-06-27 |
| DK0941329T3 (da) | 2004-11-29 |
| US6500422B2 (en) | 2002-12-31 |
| IL130168A0 (en) | 2000-06-01 |
| KR20000053291A (ko) | 2000-08-25 |
| JP2001505770A (ja) | 2001-05-08 |
| AU733825B2 (en) | 2001-05-24 |
| EP0941329A1 (en) | 1999-09-15 |
| CA2272130A1 (en) | 1998-06-04 |
| EA199900507A1 (ru) | 2000-02-28 |
| ES2225901T3 (es) | 2005-03-16 |
| ZA9710737B (en) | 1998-07-30 |
| EP0941329B1 (en) | 2004-07-21 |
| ATE271607T1 (de) | 2004-08-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2205792T3 (es) | Celulas madre mesenquimatosas como inmunosupresores. | |
| UA73270C2 (en) | Application of genetically structured cells expressing lymphocytes activation gene (lag-3) on the surface for protection of transplant against rejection and a method for induction of specific protection against rejection of material being tranplanted | |
| US8071085B2 (en) | Primary cultured adipocytes for gene therapy | |
| Yasuda et al. | Local expression of immunoregulatory IL-12p40 gene prolonged syngeneic islet graft survival in diabetic NOD mice. | |
| JP6018081B2 (ja) | 自己免疫および炎症性疾患におけるリンパ系内投与用の脂肪由来間葉系幹細胞 | |
| US9592259B2 (en) | APC-mediated tolerance induction for therapy of multiple sclerosis | |
| Tamura et al. | Targeted killing of migrating glioma cells by injection of HTK-modified glioma cells | |
| MXPA99004550A (es) | Célula genéticamente modificada capaz de inducir protección contra el rechazo de injerto en transplante y uso como medicamento | |
| Whartenby et al. | Gene therapy: clinical potential and relationships to drug treatment | |
| JP4879867B2 (ja) | 遺伝子治療用初代培養脂肪細胞 | |
| Hawthorne | Beta cell therapies for type 1 diabetes | |
| CA2158933A1 (en) | Methods of suppressing graft rejection | |
| ROY et al. | Gene therapy: current status and future | |
| Tremblay | Immune Reaction Following Cell and Gene Therapy | |
| Gainer | Biolistic transfection of immunomodulating genes into mouse islets to promote allograft survival. | |
| Hotel et al. | The Australasian Gene Therapy Society | |
| Magee et al. | GENE THERAPY IN ORGAN | |
| Ma et al. | 984. Liver Restricted Expression of Canine Iduronidase Does Not Prevent a CTL Response in Adult MPS I Mice after Retroviral Vector-Mediated Gene Therapy, but Transient Immunomodulation with CTLA4-Ig Combined with Anti-CD4 or Anti-CD40 Ligand Does | |
| KR20050024341A (ko) | 유전자 치료용 초대 배양 지방세포 |